Lung Adenocarcinoma: Mutation Analysis (MutSig v2.0)
Maintained by Dan DiCara (Broad Institute)
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.

  • Working with individual set: LUAD

  • Number of patients in set: 229

Input

The input for this pipeline is a set of individuals with the following files associated for each:

  1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

  2. A .wig file that contains information about the coverage of the sample.

Summary

  • MAF used for this analysis:LUAD.final_analysis_set.maf

  • Significantly mutated genes (q ≤ 0.1): 188

  • Mutations seen in COSMIC: 515

  • Significantly mutated genes in COSMIC territory: 24

  • Genes with clustered mutations (≤ 3 aa apart): 388

  • Significantly mutated genesets: 16

  • Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

  • Read 229 MAFs of type "Broad"

  • Total number of mutations in input MAFs: 251233

  • After removing 79 mutations outside chr1-24: 251154

  • After removing 145352 noncoding mutations: 105802

  • After collapsing adjacent/redundant mutations: 94321

Mutation Filtering

  • Number of mutations before filtering: 94321

  • After removing 1304 mutations outside gene set: 93017

  • After removing 401 mutations outside category set: 92616

Results
Breakdown of Mutations by Type

Table 1.  Get Full Table Table representing breakdown of mutations by type.

type count
Frame_Shift_Del 1341
Frame_Shift_Ins 558
In_Frame_Del 200
In_Frame_Ins 27
Missense_Mutation 60650
Nonsense_Mutation 4843
Nonstop_Mutation 58
Silent 22937
Splice_Site 1868
Translation_Start_Site 134
Total 92616
Breakdown of Mutation Rates by Category Type

Table 2.  Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category n N rate rate_per_mb relative_rate exp_ns_s_ratio
*CpG->A 8889 379287204 0.000023 23 2.3 2.1
*Cp(A/C/T)->A 22064 3108508517 7.1e-06 7.1 0.7 5
C->(T/G) 19000 3487795721 5.4e-06 5.4 0.53 2.8
A->mut 10782 3354933814 3.2e-06 3.2 0.32 3.9
indel+null 8797 6842729535 1.3e-06 1.3 0.13 NaN
double_null 147 6842729535 2.1e-08 0.021 0.0021 NaN
Total 69679 6842729535 1e-05 10 1 3.5
Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1. 

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2.  Patients counts and rates file used to generate this plot: LUAD.patients.counts_and_rates.txt

CoMut Plot

Figure 3.  Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

  • N = number of sequenced bases in this gene across the individual set

  • n = number of (nonsilent) mutations in this gene across the individual set

  • npat = number of patients (individuals) with at least one nonsilent mutation

  • nsite = number of unique sites having a non-silent mutation

  • nsil = number of silent mutations in this gene across the individual set

  • n1 = number of nonsilent mutations of type: *CpG->A

  • n2 = number of nonsilent mutations of type: *Cp(A/C/T)->A

  • n3 = number of nonsilent mutations of type: C->(T/G)

  • n4 = number of nonsilent mutations of type: A->mut

  • n5 = number of nonsilent mutations of type: indel+null

  • n6 = number of nonsilent mutations of type: double_null

  • p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene

  • p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene

  • p_ks = p-value for clustering of mutations (Kolmogorov-Smirnoff test)

  • p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene

  • p_joint = p-value for clustering + conservation

  • p = p-value (overall)

  • q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3.  Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 188. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank gene description N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_classic p_ns_s p_ks p_cons p_joint p q
1 KRTAP5-5 keratin associated protein 5-5 155262 23 23 6 5 1 3 0 0 19 0 1.13e-14 0.99 2e-07 1 0.000032 0.000 0.000
2 STK11 serine/threonine kinase 11 199230 21 20 20 0 0 4 2 4 11 0 5.66e-15 0.01 0.00036 0.014 0.0003 1.11e-16 1.00e-12
3 KEAP1 kelch-like ECH-associated protein 1 418841 39 39 37 0 4 8 13 10 4 0 2.33e-15 0.000026 0.07 0.009 0.011 9.99e-16 1.81e-12
4 TP53 tumor protein p53 288082 126 117 104 2 8 22 31 18 47 0 <1.00e-15 1.2e-10 2e-07 2e-07 0 <1.00e-15 <1.81e-12
5 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 161903 60 60 6 0 0 47 10 3 0 0 <1.00e-15 0.002 2e-07 2e-07 0 <1.00e-15 <1.81e-12
6 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) 918061 33 27 19 7 2 5 4 13 9 0 0.00167 0.65 2e-07 0.0012 0 <1.00e-15 <1.81e-12
7 ASTN2 astrotactin 2 839056 29 23 29 7 4 12 5 4 4 0 0.380 0.31 6e-07 0.00035 0 <1.00e-15 <1.81e-12
8 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 226023 14 14 14 1 0 1 4 4 5 0 5.10e-09 0.26 0.000016 4e-07 0 <1.00e-15 <1.81e-12
9 OR6C4 olfactory receptor, family 6, subfamily C, member 4 213428 3 3 3 1 0 0 2 0 1 0 0.146 0.64 0.0029 0.00057 0 <1.00e-15 <1.81e-12
10 ROPN1 ropporin, rhophilin associated protein 1 139461 3 3 3 0 1 0 2 0 0 0 0.217 0.29 0.089 0.0091 0 <1.00e-15 <1.81e-12
11 NAV3 neuron navigator 3 1659792 66 52 66 4 4 36 16 6 3 1 1.07e-13 0.0026 0.32 0.48 0.4 1.37e-12 2.25e-09
12 MAGEC1 melanoma antigen family C, 1 774020 40 34 39 2 2 14 13 7 4 0 1.30e-13 0.0051 0.69 0.38 0.67 2.72e-12 4.10e-09
13 CDH10 cadherin 10, type 2 (T2-cadherin) 552119 51 40 51 8 4 27 12 1 7 0 2.21e-11 0.27 0.82 0.44 0.77 4.42e-10 5.92e-07
14 TMTC1 transmembrane and tetratricopeptide repeat containing 1 543417 32 26 30 3 3 17 7 3 2 0 4.81e-11 0.055 0.92 0.1 0.37 4.58e-10 5.92e-07
15 MUC7 mucin 7, secreted 261518 19 17 19 1 0 8 3 5 3 0 2.86e-10 0.091 0.04 0.53 0.08 5.79e-10 6.99e-07
16 EPHA6 EPH receptor A6 755242 33 30 33 4 3 17 7 3 3 0 7.58e-09 0.17 0.11 0.0023 0.004 7.70e-10 8.70e-07
17 ZNF676 zinc finger protein 676 407391 22 21 21 2 0 10 9 0 3 0 6.20e-09 0.25 0.0039 0.23 0.007 1.08e-09 1.15e-06
18 OR4C16 olfactory receptor, family 4, subfamily C, member 16 214115 15 14 14 0 0 9 2 3 1 0 1.57e-08 0.035 0.0019 0.17 0.0034 1.33e-09 1.33e-06
19 RIMS2 regulating synaptic membrane exocytosis 2 994318 45 39 45 4 4 16 10 8 7 0 2.99e-09 0.051 0.14 0.14 0.095 6.55e-09 6.23e-06
20 GABRB3 gamma-aminobutyric acid (GABA) A receptor, beta 3 314646 18 17 18 1 3 6 4 4 1 0 1.66e-08 0.038 0.015 0.39 0.028 1.05e-08 9.49e-06
21 OR2L3 olfactory receptor, family 2, subfamily L, member 3 215947 16 15 16 2 1 9 2 4 0 0 1.81e-09 0.19 0.34 0.68 0.59 2.30e-08 1.98e-05
22 CD5L CD5 molecule-like 244572 15 15 15 1 3 3 0 5 4 0 1.22e-08 0.1 0.25 0.066 0.11 2.86e-08 2.24e-05
23 CNBD1 cyclic nucleotide binding domain containing 1 238160 14 14 14 1 0 5 3 4 2 0 7.99e-09 0.32 0.4 0.056 0.17 2.96e-08 2.24e-05
24 ELTD1 EGF, latrophilin and seven transmembrane domain containing 1 482503 20 20 20 0 0 4 4 8 4 0 1.39e-09 0.015 0.61 0.54 1 2.98e-08 2.24e-05
25 KRTAP1-5 keratin associated protein 1-5 121141 7 7 2 1 0 0 0 6 1 0 3.20e-06 0.64 0.000099 0.98 0.00048 3.30e-08 2.39e-05
26 TRIM58 tripartite motif-containing 58 254648 15 15 15 2 1 3 3 5 3 0 5.51e-08 0.19 0.029 0.18 0.034 3.94e-08 2.68e-05
27 OR2T4 olfactory receptor, family 2, subfamily T, member 4 240679 18 17 18 2 1 7 8 2 0 0 1.02e-08 0.071 0.12 0.87 0.19 4.10e-08 2.68e-05
28 REG3A regenerating islet-derived 3 alpha 125492 15 14 14 2 0 4 7 2 2 0 4.10e-09 0.25 0.31 0.54 0.48 4.14e-08 2.68e-05
29 BRAF v-raf murine sarcoma viral oncogene homolog B1 510899 17 17 12 1 1 7 2 5 2 0 5.99e-07 0.096 0.0088 0.16 0.018 2.10e-07 0.000131
30 OR4A5 olfactory receptor, family 4, subfamily A, member 5 218008 13 12 13 0 1 4 3 4 1 0 3.67e-08 0.035 0.27 0.63 0.42 2.92e-07 0.000171
31 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 134194 4 4 2 1 0 1 0 3 0 0 0.0161 0.71 4e-07 0.19 1e-06 3.04e-07 0.000171
32 SPRR3 small proline-rich protein 3 117706 7 7 4 0 0 1 0 1 5 0 1.29e-05 0.62 0.0024 0.046 0.0013 3.07e-07 0.000171
33 REG1B regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) 119309 14 13 14 2 1 7 1 3 2 0 1.47e-07 0.39 0.5 0.04 0.11 3.12e-07 0.000171
34 BAGE2 B melanoma antigen family, member 2 79234 9 9 9 0 0 4 2 1 2 0 2.11e-08 0.12 0.86 0.44 0.88 3.49e-07 0.000186
35 OR2L8 olfactory receptor, family 2, subfamily L, member 8 215947 15 13 13 2 1 8 3 2 1 0 3.08e-07 0.23 0.072 0.19 0.094 5.34e-07 0.000276
COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4.  Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 24. Number of genes displayed: 10

rank gene description n cos n_cos N_cos cos_ev p q
1 LRP1B low density lipoprotein-related protein 1B (deleted in tumors) 149 18 8 4122 8 3.9e-14 1.8e-10
2 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 60 51 60 11679 797017 1e-13 2.3e-10
3 BRAF v-raf murine sarcoma viral oncogene homolog B1 17 88 12 20152 21212 1.6e-13 2.4e-10
4 STK11 serine/threonine kinase 11 21 130 14 29770 27 2.2e-13 2.5e-10
5 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) 33 218 29 49922 10294 3e-13 2.6e-10
6 TP53 tumor protein p53 126 308 121 70532 18205 3.4e-13 2.6e-10
7 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 14 315 14 72135 259 4.2e-13 2.7e-10
8 MET met proto-oncogene (hepatocyte growth factor receptor) 12 33 6 7557 64 2.7e-10 1.5e-07
9 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 11 184 9 42136 3946 9.2e-10 4.6e-07
10 NF1 neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) 29 285 9 65265 13 3.8e-08 0.000017

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5.  Get Full Table Genes with Clustered Mutations

num gene desc n mindist nmuts0 nmuts3 nmuts12 npairs0 npairs3 npairs12
6688 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 60 0 1382 1488 1488 1382 1488 1488
13091 TP53 tumor protein p53 126 0 53 200 636 53 200 636
3862 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) 33 0 39 60 60 39 60 60
6750 KRTAP1-5 keratin associated protein 1-5 7 0 15 15 15 15 15 15
9561 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 11 0 6 10 11 6 10 11
8465 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 4 0 6 6 6 6 6 6
13295 TSHZ3 teashirt zinc finger homeobox 3 39 0 5 14 29 5 14 29
1224 BRAF v-raf murine sarcoma viral oncogene homolog B1 17 0 5 9 13 5 9 13
6426 KEAP1 kelch-like ECH-associated protein 1 39 0 4 17 44 4 17 44
14412 ZNF536 zinc finger protein 536 54 0 4 11 28 4 11 28

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6.  Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 16. Number of genesets displayed: 10

rank geneset description genes N_genes mut_tally N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_ns_s p q
1 PLK3PATHWAY Active Plk3 phosphorylates CDC25c, blocking the G2/M transition, and phosphorylates p53 to induce apoptosis. ATM, ATR, CDC25C, CHEK1, CHEK2, CNK, TP53, YWHAH 7 ATM(22), ATR(17), CDC25C(3), CHEK1(6), CHEK2(2), TP53(126) 5517526 176 134 153 7 10 35 48 28 55 0 1e-08 2e-15 3.8e-13
2 TERTPATHWAY hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 7 HDAC1(3), MAX(3), SP1(1), SP3(4), TP53(126), WT1(8) 2427858 145 120 123 10 9 29 35 21 51 0 1.2e-06 3.4e-15 3.8e-13
3 RNAPATHWAY dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 9 CHUK(3), DNAJC3(3), MAP3K14(1), NFKB1(3), NFKBIA(1), TP53(126) 3372941 137 119 115 9 9 23 36 18 51 0 2.2e-06 3.8e-15 3.8e-13
4 ARFPATHWAY Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 16 ABL1(2), CDKN2A(14), E2F1(3), MDM2(2), PIK3CA(11), PIK3R1(3), POLR1A(8), POLR1B(10), POLR1D(2), RB1(13), TBX2(1), TP53(126), TWIST1(1) 7038773 196 131 170 15 16 33 53 29 65 0 2.8e-08 4.7e-15 3.8e-13
5 PMLPATHWAY Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 13 CREBBP(4), DAXX(6), HRAS(1), PAX3(6), PML(7), RARA(3), RB1(13), SIRT1(1), SP100(9), TNFRSF1B(1), TP53(126) 6622222 177 129 155 15 14 30 47 25 61 0 3.8e-07 4.9e-15 3.8e-13
6 P53PATHWAY p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 16 APAF1(8), ATM(22), BAX(1), BCL2(1), CCND1(2), CCNE1(3), CDK2(4), CDK4(2), CDKN1A(1), E2F1(3), GADD45A(1), MDM2(2), PCNA(1), RB1(13), TP53(126) 6266585 190 141 167 16 16 37 42 29 66 0 1.9e-06 5.1e-15 3.8e-13
7 P53HYPOXIAPATHWAY Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 19 ABCB1(20), ATM(22), BAX(1), CDKN1A(1), CPB2(4), CSNK1A1(1), CSNK1D(2), GADD45A(1), HIF1A(1), IGFBP3(2), MAPK8(3), MDM2(2), NQO1(3), TP53(126) 7172280 189 136 165 18 17 40 45 27 60 0 0.000012 5.3e-15 3.8e-13
8 TIDPATHWAY On ligand binding, interferon gamma receptors stimulate JAK2 kinase to phosphorylate STAT transcription factors, which promote expression of interferon responsive genes. DNAJA3, HSPA1A, IFNG, IFNGR1, IFNGR2, IKBKB, JAK2, LIN7A, NFKB1, NFKBIA, RB1, RELA, TIP-1, TNF, TNFRSF1A, TNFRSF1B, TP53, USH1C, WT1 18 IFNG(4), IFNGR1(3), IFNGR2(3), IKBKB(3), JAK2(4), LIN7A(2), NFKB1(3), NFKBIA(1), RB1(13), TNFRSF1B(1), TP53(126), USH1C(4), WT1(8) 6332308 175 131 153 16 15 35 41 21 63 0 1.8e-06 5.8e-15 3.8e-13
9 SA_G1_AND_S_PHASES Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 15 ARF3(1), CCND1(2), CDK2(4), CDK4(2), CDKN1A(1), CDKN1B(3), CDKN2A(14), E2F1(3), MDM2(2), NXT1(1), PRB1(3), TP53(126) 2958909 162 124 140 8 15 29 38 24 56 0 1.1e-09 6e-15 3.8e-13
10 RBPATHWAY The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH 12 ATM(22), CDC25A(4), CDC25B(1), CDC25C(3), CDK2(4), CDK4(2), CHEK1(6), MYT1(6), RB1(13), TP53(126), WEE1(3) 6070332 190 138 167 13 15 37 43 29 66 0 1.6e-07 6.2e-15 3.8e-13

Table 7.  Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank geneset description genes N_genes mut_tally N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_ns_s p q
1 FBW7PATHWAY Cyclin E interacts with cell cycle checkpoint kinase cdk2 to allow transcription of genes required for S phase, including transcription of additional cyclin E. CCNE1, CDC34, CDK2, CUL1, E2F1, FBXW7, RB1, SKP1A, TFDP1 8 CCNE1(3), CDC34(1), CDK2(4), CUL1(6), E2F1(3), FBXW7(4), RB1(13), TFDP1(3) 2895018 37 30 37 3 5 8 9 6 9 0 0.023 0.063 1
2 P27PATHWAY p27 blocks the G1/S transition by inhibiting the checkpoint kinase cdk2/cyclin E and is inhibited by cdk2-mediated ubiquitination. CCNE1, CDK2, CDKN1B, CKS1B, CUL1, E2F1, NEDD8, RB1, RBX1, SKP1A, SKP2, TFDP1, UBE2M 12 CCNE1(3), CDK2(4), CDKN1B(3), CUL1(6), E2F1(3), NEDD8(2), RB1(13), SKP2(4), TFDP1(3), UBE2M(1) 2978832 42 33 42 5 5 8 11 7 11 0 0.051 0.11 1
3 IL18PATHWAY Pro-inflammatory IL-18 is activated in macrophages by caspase-1 cleavage and, in conjunction with IL-12, stimulates Th1 cell differentiation. CASP1, IFNG, IL12A, IL12B, IL18, IL2 6 CASP1(2), IFNG(4), IL12A(3), IL2(5) 1033019 14 12 13 1 2 7 2 2 1 0 0.15 0.23 1
4 HSA00130_UBIQUINONE_BIOSYNTHESIS Genes involved in ubiquinone biosynthesis COQ2, COQ3, COQ5, COQ6, COQ7, ND1, ND2, ND3, ND4, ND4L, ND5, ND6, NDUFA12, NDUFA13, NDUFB11 8 COQ3(4), COQ5(5), COQ6(3), COQ7(1), NDUFA12(2), NDUFA13(4), NDUFB11(1) 1380412 20 14 20 2 5 5 5 1 4 0 0.082 0.31 1
5 BOTULINPATHWAY Blockade of Neurotransmitter Relase by Botulinum Toxin CHRM1, CHRNA1, SNAP25, STX1A, VAMP2 5 CHRM1(2), CHRNA1(7), SNAP25(4), STX1A(3) 1118665 16 13 16 3 5 3 5 1 2 0 0.2 0.35 1
6 HSA00902_MONOTERPENOID_BIOSYNTHESIS Genes involved in monoterpenoid biosynthesis CYP2C19, CYP2C9 2 CYP2C19(9), CYP2C9(3) 690893 12 11 12 3 2 3 3 2 2 0 0.54 0.4 1
7 SKP2E2FPATHWAY E2F-1, a transcription factor that promotes the G1/S transition, is repressed by Rb and activated by cdk2/cyclin E. CCNA1, CCNE1, CDC34, CDK2, CUL1, E2F1, RB1, SKP1A, SKP2, TFDP1 9 CCNA1(2), CCNE1(3), CDC34(1), CDK2(4), CUL1(6), E2F1(3), RB1(13), SKP2(4), TFDP1(3) 2974481 39 31 39 6 6 9 9 6 9 0 0.12 0.42 1
8 HSA00730_THIAMINE_METABOLISM Genes involved in thiamine metabolism LHPP, MTMR1, MTMR2, MTMR6, NFS1, PHPT1, THTPA, TPK1 8 LHPP(2), MTMR1(5), MTMR2(2), MTMR6(6), NFS1(4), PHPT1(1), TPK1(5) 2218323 25 20 25 3 1 9 6 7 1 1 0.15 0.54 1
9 HSA00031_INOSITOL_METABOLISM Genes involved in inositol metabolism ALDH6A1, TPI1 2 TPI1(6) 566088 6 5 6 0 0 3 2 1 0 0 0.24 0.6 1
10 INOSITOL_METABOLISM ALDH6A1, ALDOA, ALDOB, ALDOC, TPI1 5 ALDOA(2), ALDOB(4), ALDOC(1), TPI1(6) 1340337 13 10 13 0 0 5 4 2 2 0 0.043 0.72 1
Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2012 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle